Point72 (DIFC)’s Corcept Therapeutics CORT Stock Holding History

Point72 (DIFC)’s Portfolio CORT Stock Details CORT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q2	–	Sell	-10,639	Closed	-$268K	–	1531
2024 Q1	$268K	Buy	+10,639	New	+$251K	0.01%	897

Other funds holding CORT

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

ISL

Ingalls & Snyder LLC New York $3.66B AUM 57.76% 1-Year Est. Return

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

Parallel Advisors San Francisco, California $6.56B AUM 32.24% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return

NHAS

Novo Holdings A/S Hellerup, Denmark $1.72B AUM 106.92% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

BTW

Boston Trust Walden Boston, Massachusetts $13.1B AUM 24.63% 1-Year Est. Return

Point72 (DIFC)'s CORT Position: Q2 2024 in Review

Point72 (DIFC) sold out of Corcept Therapeutics (CORT) in Q2 2024, closing a stake of 10,639 shares — an estimated $268K sold.

Point72 (DIFC) first reported a position in CORT in Q1 2024 and held it in 1 quarter. The position peaked at $268K in Q1 2024. 286 funds tracked by Wall St. Rank hold CORT as of Q2 2024.

Point72 (DIFC) reported no remaining Corcept Therapeutics position as of Q2 2024 after selling out during the quarter.
Point72 (DIFC) sold 10,639 Corcept Therapeutics shares in Q2 2024, an estimated $268K.
Point72 (DIFC) first reported a position in Corcept Therapeutics in Q1 2024 and held it in 1 quarter.
Point72 (DIFC)'s Corcept Therapeutics position peaked at $268K in Q1 2024.
286 funds tracked by Wall St. Rank held Corcept Therapeutics as of Q2 2024.

Based on Point72 (DIFC)'s 13F filing for Q2 2024, filed 14 Aug 2024.